Monitoring early tumor response to drug therapy with diffuse optical tomography

Journal of Biomedical Optics

Volumn 17, Issue 1, 2012, Pages

  Flexman, Molly L ^a   Vlachos, Fotios ^a   Kim, Hyun Keol ^a   Sirsi, Shashank R ^a,b   Huang, Jianzhong ^c   Hernandez, Sonia L ^c   Johung, Tessa B ^c   Gander, Jeffrey W ^c   Reichstein, Ari R ^c   Lampl, Brooke S ^c   Wang, Antai ^d   Borden, Mark A ^a,b   Yamashiro, Darrell J ^c   Kandel, Jessica J ^c   Hielscher, Andreas H ^a,c  

^a Department of Earth and Environmental Sciences   (United States)

^b University of Colorado at Boulder   (United States)

^c Department of Mechanical Engineering ^*  (United States)

^d Department of Medicine   (United States)

Author keywords

Angiogenesis; Avastin ; Bevacizumab; Cancer imaging; Diffuse optical imaging; Diffuse optical tomography; Magnetic resonance imaging; Therapy response

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; DEOXYHEMOGLOBIN; FLUORESCENT DYE; HEMOGLOBIN; MONOCLONAL ANTIBODY; OXYHEMOGLOBIN; PLANT LECTIN;

ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; DRUG MONITORING; DRUG SCREENING; EXPERIMENTAL NEOPLASM; FEMALE; METABOLISM; METHODOLOGY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; OPTICAL TOMOGRAPHY; SCINTIGRAPHY; VASCULARIZATION;

ANALYSIS OF VARIANCE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG MONITORING; FEMALE; FLUORESCENT DYES; HEMOGLOBINS; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; OXYHEMOGLOBINS; PERFUSION IMAGING; PLANT LECTINS; TOMOGRAPHY, OPTICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861426451     PISSN: 10833668     EISSN: 15602281     Source Type: Journal    
DOI: 10.1117/1.JBO.17.1.016014     Document Type: Article

References (37)

1. J. Folkman, "Tumor angiogenesis: therapeutic implications," N. Engl. J. Med. 285(21), 1182-1186 (1971).
2. J. G. Bender et al., "Vascular remodeling and clinical resistance to antiangiogenic cancer therapy," Drug Resist. Updates 7(4-5), 289-300 (2004).
3. F. Kabbinavar et al., "Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer," J. Clin. Oncol. 21(1), 60-65 (2003).
4. H. Hurwitz et al., "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer," N. Engl. J. Med. 350(23), 2335-2342 (2004). (Pubitemid 38702844)
5. R. Pazdur, "FDA approval for bevacizumab," (2009), http://www.cancer .gov/cancertopics/druginfo/fda-bevacizumab.
6. K. J. Kim et al., "Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumor growth in vivo," Nature 362(6423), 841-844 (1993). (Pubitemid 23132159)
7. G. Bergers and D. Hanahan, "Modes of resistance to anti-angiogenic therapy," Nat. Rev. Cancer. 8(8), 592-603 (2008).
8. K. Mulder et al., "The role of bevacizumab in colorectal cancer: understanding its benefits and limitations," Expert Opin. Biol. Ther. 11(3), 405-413 (2011).
9. G. Niu and X. Chen, "PET imaging of angiogenesis," PET Clin. 4(1), 11 (2010).
10. S. Zwick et al., "Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging," J. Magn. Reson. Imag. 29(5), 1125-1133 (2009).
11. M. Lamuraglia et al., "Clinical relevance of contrast-enhanced ultrasound in monitoring anti-angiogenic therapy of cancer: Current status and perspectives," Crit. Rev. Oncol. Hematol. 73(3), 202-212 (2010).
12. J. G. Penfield, "Nephrogenic systemic fibrosis and the use of gadolinium- based contrast agents," Pediatr. Nephrol. 23(12), 2121-2129 (2008).
13. B. J. Tromberg et al., "Assessing the future of diffuse optical imaging technologies for breast cancer management," Med. Phys. 35(6), 2443-2451 (2008). (Pubitemid 351748652)
14. A. Custo et al., "Anatomical atlas-guided diffuse optical tomography of brain activation," Neuroimage. 49(1), 561-567 (2010).
15. A. H. Hielscher et al., "Frequency-domain optical tomography imaging of arthritic finger joints," IEEE Trans. Med. Imag. 30(10), 1725-1736 (2011).
16. M. A. Smith et al., "SK-NEP-1 and Rhl are Ewing family tumor lines," Pediatr. Blood. Canc. 50(3), 703-706 (2008). (Pubitemid 351155868)
17. J. Z. Huang et al., "Regression of established tumors and metastases by potent vascular endothelial growth factor blockade," Proc. Natl. Acad. Sci. U.S.A 100(13), 7785-7790 (2003).
18. E. S. Kim et al., "Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma," Proc. Natl. Acad. Sci. U.S.A 99(17), 11399-11404 (2002). (Pubitemid 34920937)
19. D. H. Rowe et al., "Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor," J. Pediatr. Surg. 35(1), 30-32 (2000).
20. D. H. Rowe et al., "Suppression of primary tumor growth in a mouse model of human neuroblastoma," J. Pediatr. Surg. 35(6), 977-981 (2000). (Pubitemid 30346200)
21. J. M. Lasker et al., "Digital-signal-processor-based dynamic imaging system for optical tomography," Rev. Sci. Instrum. 78(8), 08706 (2007).
22. H. K. Kim et al., "PDE-constrained multispectral imaging of tissue chromophores with the equation of radiative transfer," Biomed. Opt. Express. 1(3), 12 (2010).
23. R. R. Edelman et al., Clinical Magnetic Resonance Imaging, Elsevier, Philadelphia, PA (2005).
24. K. M. Johnson et al., "Gadolinium-bearing red cells as blood pool MRI contrast agents," Magn. Reson. Mater. Med. 40(1), 133-142 (1998). (Pubitemid 28292595)
25. M. H. Teicher et al., "Functional deficits in basal ganglia of children with attention-deficit/hyperactivity disorder shown with functional magnetic resonance imaging relaxometry," Nat. Med. 6(4), 470-473 (2000). (Pubitemid 30208168)
26. S. Remmele et al., "Concurrent MR blood volume and vessel size estimation in tumors by Robust and simultaneous δR2 and δR2- quantification," Magn. Reson. Mater. Med. 66(1), 144-153 (2011).
27. G. Gambarota et al., "Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI," Br. J. Canc. 98 (11), 1784-1789 (2008). (Pubitemid 351748852)
28. C. M. Anderson et al., "Brain T2 relaxation times correlate with regional cerebral blood volume," Magn. Reson. Mater. Phys., Biol. Med. 18(1), 3-6 (2005). (Pubitemid 40576538)
29. H. Moreno et al., "Longitudinal mapping of mouse cerebral blood volume with MRI," NMR Biomed. 19(5), 535-543 (2006).
30. R. Wild et al., "Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density," Microvasc. Res. 59(3), 368-376 (2000). (Pubitemid 30322264)
31. J. Huang et al., "TNP-470 promotes initial vascular sprouting in xenograft tumors," Mol. Canc. Therapeut. 3(3), 335-343 (2004). (Pubitemid 39193709)
32. N. M. Laird and J. H. Ware, "Random-effects models for longitudinal data," Biometrics. 38(4), 963-974 (1982).
33. R. K. Jain, "Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy," Science 307(5706), 58-62 (2005). (Pubitemid 40093472)
34. M. M. Darpolor, R. C. Molthen, and K. M. Schmainda, "Multimodality Imaging of abnormal vascular perfusion and morphology in Preclinical 9L Gliosarcoma Model," PloS One. 6(1) (2011).
35. R. C. Mesquita et al., "Direct measurement of tissue blood flow and metabolism with diffuse optics," Philos. Transact. A Math. Phys. Eng. Sci. 369(1955), 4390-4406 (2011).
36. M. Eisenblatter et al., "Optical techniques for the molecular imaging of angiogenesis," Eur. J. Nucl. Med. Mol. Imag. 37, S127-S137 (2010).
37. D. R. Busch et al., "Computer aided automatic detection of malignant lesions in diffuse optical mammography," Med. Phys. 37(4), 1840-1849 (2010).